Evidence map›Paper›PMID 26100716›Full record

ArticleAntimicrobial agents and chemotherapy2015

Interactions between QnrB, QnrB mutants, and DNA gyrase.

Eu Suk Kim, Chunhui Chen, Molly Braun, Hyo Youl Kim, Ryo Okumura, Yin Wang, George A Jacoby, David C Hooper

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Eu Suk KimDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Chunhui ChenDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA Institute of Antibiotics, Huashan Hospital, Fudan University, and Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.
Molly BraunDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Hyo Youl KimDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
Ryo OkumuraDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA Biological Research Laboratories, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
Yin WangDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
George A JacobyLahey Hospital and Medical Center, Burlington, Massachusetts, USA.
David C HooperDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA dhooper@mgh.harvard.edu.
Massachusetts General Hospital · USDaiichi-Sankyo (Japan) · JPHuashan Hospital · CNLahey Medical Center · USSeoul National University Bundang Hospital · KR

Funding

Plasmid-mediated Quinolone ResistanceR01AI057576 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HOOPER, DAVID C · 2004 to 2018
$5.3M
NIAID NIH HHS R01 AI057576
6 · The paper itself

Abstract

Plasmid-encoded protein QnrB1 protects DNA gyrase from ciprofloxacin inhibition. Using a bacterial two-hybrid system, we evaluated the physical interactions between wild-type and mutant QnrB1, the GyrA and GyrB gyrase subunits, and a GyrBA fusion protein. The interaction of QnrB1 with GyrB and GyrBA was approximately 10-fold higher than that with GyrA, suggesting that domains of GyrB are important for stabilizing QnrB1 interaction with the holoenzyme. Sub-MICs of ciprofloxacin or nalidixic acid reduced the interactions between QnrB1 and GyrA or GyrBA but produced no reduction in the interaction with GyrB or a quinolone-resistant GyrA:S83L (GyrA with S83L substitution) mutant, suggesting that quinolones and QnrB1 compete for binding to gyrase. Of QnrB1 mutants that reduced quinolone resistance, deletions in the C or N terminus of QnrB1 resulted in a marked decrease in interactions with GyrA but limited or no effect on interactions with GyrB and an intermediate effect on interactions with GyrBA. While deletion of loop B and both loops moderately reduced the interaction signal with GyrA, deletion of loop A resulted in only a small reduction in the interaction with GyrB. The loop A deletion also caused a substantial reduction in interaction with GyrBA, with little effect of loop B and dual-loop deletions. Single-amino-acid loop mutations had little effect on physical interactions except for a Δ105I mutant. Therefore, loops A and B may play key roles in the proper positioning of QnrB1 rather than as determinants of the physical interaction of QnrB1 with gyrase.

Indexed as

DNA GyraseEscherichia coliEscherichia coli ProteinsProtein BindingTwo-Hybrid System TechniquesDNA GyraseEscherichia coli ProteinsQnr protein, E coli

Identifiers

PMID26100716
PMCPMC4538543
OpenAlexW1933730518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.